pone.0226464.s007.tif (237.73 kB)
Download file

Quantification of co-treatment studies with romidepsin and MEK 1/2 inhibitors (cobimetinib or trametinib) and pre-treatment studies with romidepsin.

Download (237.73 kB)
posted on 09.10.2020, 17:29 by Tiffany C. Chang, Margarite D. Matossian, Steven Elliott, Hope E. Burks, Rachel A. Sabol, Deniz A. Ucar, Henri Wathieu, Jovanny Zabaleta, Luis De Valle, Sukhmani Gill, Elizabeth Martin, Adam I. Riker, Lucio Miele, Bruce A. Bunnell, Matthew E. Burow, Bridgette M. Collins-Burow

TU-BcX-4IC cells were concomitantly treated with romidepsin and a MEK 1/2 inhibitor. Pre-treatment with romidepsin was studied in TU-BcX-4IC cells by either pre-treating with romidepsin (50 nM) or not pre-treating for 48 hours, and then treating with cobimetinib or trametinib (1 μM). Crystal violet stained cells were lysed and absorbance was measured at 570 nm to quantify staining results.